KROS - Dosing underway for Keros Therapeutics's KER-050 in mid-stage for myelodysplastic syndromes study

Keros Therapeutics ([[KROS]] +5.9%) has dosed the first two participants in a Phase 2 clinical trial evaluating KER-050 for the treatment of anemia and thrombocytopenia in myelodysplastic syndromes ((MDS)).Keros presented data from its Phase 1 clinical trial of KER-050 in healthy post-menopausal women at the 25th Annual Congress of European Hematology Association in June 2020.The Phase 2 clinical trial will be carried in 2 parts, Part 1 will enroll ~6 participants in each up to four cohorts of ascending doses of KER-050. Part 2, the dose selected from Part 1 will be evaluated in up to 30 participants.The primary objective of the trial is evaluate the safety in MDS participants with ring sideroblasts as well as in participants without ring sideroblasts.Keros expects to report initial data from Part 1 of this trial in mid-2021.MDS is considered a type of cancer and occur when the blood-forming cells in the bone marrow become abnormal.

For further details see:

Dosing underway for Keros Therapeutics's KER-050 in mid-stage for myelodysplastic syndromes study